To date, many studies have confirmed hsa-miR-19a/b oncogenic role in TNBC tumor biology by repressing PTEN and activating NF-kB [43] and levels of circulating miR-19 correlated with response to neoadjuvant epirubicin + paclitaxel chemotherapy regimen in Stage II and III patients with luminal A breast tumors [44]. This evidence concerns the gene PTEN and breast neoplasm.